-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5163 Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Diseases, Lymphoid Malignancies
Monday, December 11, 2023, 6:00 PM-8:00 PM

Jing-Zhou Hou1,2, Simon Blanc3, Gregory A Maglinte, PhD, MPH4*, Anupama Vasudevan3*, Anna Rui3*, Michael Gart, MBA5*, Hoa Pham, PharmD4*, Lindsay Aton, MHSA3*, Brandon Wang3* and Rushir Choksi6*

1Hematology and BMT, Lemieux Center for Blood Cancers, UPMC Hillman Cancer Center, Pittsburgh, PA
2University of Pittsburgh Medical Center, Pittsburgh, PA
3Integra Connect PrecisionQ, West Palm Beach, FL
4BeiGene USA, Inc, San Mateo, CA
5Integra Connect, West Palm Beach, FL
6University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

Background: BTKis have become the standard-of-care therapies for both frontline (1L) and relapsed/refractory (2L) CLL/SLL, and recently the NCCN listed both second-generation BTKis, zanubrutinib and acalabrutinib, as preferred agents over the first-generation BTKi ibrutinib based on toxicity profile. The objective of this study was to assess real-world clinical characteristics, treatment patterns, and adverse events (AEs) among BTKi-treated patients with CLL/SLL.

Methods: This was a retrospective observational study of adult patients with CLL/SLL who initiated treatment between 01-Jan-2020 and 28-Feb-2023 in the community oncology setting across the US and were followed up through 31-May-2023. Included patients had to have at least 5 CLL/SLL visits or more CLL/SLL visits than non-CLL/SLL visits; all patients had to have 2 or more evaluation and management visits. The study included structured electronic health data from the Integra Connect-PrecisionQ de-identified real-world database. Descriptive analyses were conducted including all patients who received a BTKi, and a Kaplan-Meier analysis was performed for time-to-event outcomes.

Results: A total of 2650 patients who received a BTKi were included in the study (2465: BTKi 1L; 185: BTKi naïve in 1L with use of BTKi in subsequent lines). The median (range) age of patients in the 1L BTKi and BTKi-later line groups was 71 (35-89) and 74 (42-89) years, respectively, and most included patients were male (Table).

In 1L, 53.3% (n=1314/2465) were treated with ibrutinib, 43.3% (n=1068/2465) with acalabrutinib, and 3.4% (n=83/2465) with zanubrutinib. Among BTKi-later line patients, similar trends (45.9% [85/185] ibrutinib, 42.7% [79/185] acalabrutinib, 11.4% [21/185] zanubrutinib) were observed in 2L. The rates of cardiovascular AEs within the first 3 and 6 months of BTKi initiation were 10.1% (n=106/1048) and 13.4% (n=123/921) for patients treated with ibrutinib, 7.3% (n=56/767) and 9.8% (n=62/631) for acalabrutinib, and 7.3% (n=5/69) and 7.5% (n=3/40) for zanubrutinib, respectively.

More than 10% of ibrutinib-treated patients discontinued therapy and switched to a second-generation BTKi. The median time to treatment discontinuation (95% CI) in the 1L setting was 12.7 (11.7, 15.3) months for ibrutinib, 15.7 (12.0, 20.4) months for acalabrutinib, and 12.9 (10.3, NR) months for zanubrutinib. The proportion of patients continuing treatment at 6 and 12 months was higher with zanubrutinib (72.3% and 61.4%, respectively) compared to acalabrutinib (62.6% and 53.1%) and ibrutinib (62.3% and 51.9%). The median time to next treatment (TTNT) (95% CI) was not reached (NR) (12.6 months, NR) for those who received zanubrutinib in the 1L, while it was 31.3 (26.5, 35.5) months for ibrutinib and 35.8 (31.8, NR) months for acalabrutinib.

Conclusions: This study found that cardiovascular AEs at 6 months were higher among patients who received ibrutinib and acalabrutinib compared to zanubrutinib. While the study is limited by the smaller sample size and shorter follow-up period for the zanubrutinib group, the proportions of patients remaining on treatment were higher and the median TTNT was longer for patients who received zanubrutinib.

Disclosures: Hou: AbbVie: Consultancy; AstraZeneca: Consultancy; Genentech: Consultancy. Blanc: IntegraConnect, Precision Q: Current Employment. Maglinte: BeiGene: Current Employment; CRISPR Therapeutics: Ended employment in the past 24 months; Gilead: Current equity holder in publicly-traded company; Amgen: Current equity holder in publicly-traded company; BMS: Current equity holder in publicly-traded company. Vasudevan: IntegraConnect, Precision Q: Current Employment. Rui: BeiGene: Research Funding; Janssen: Research Funding; Click Therapeutics: Research Funding. Gart: Integra Connect: Current Employment. Pham: BeiGene: Current Employment. Wang: IntegraConnect, Precision Q: Current Employment. Choksi: Integra Connect: Consultancy, Other: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and support for attending meetings and/or travel .

*signifies non-member of ASH